AbbVie’s Steve England Joins 3Scan as Chief Science Officer

3Scan has appointed Steve England to serve as the San Francisco company’s chief science officer. England most recently worked at AbbVie (NYSE: [[ticker:ABBV]]), where he led a team focused on therapy development and emerging technology. His experience also includes drug discovery positions at AstraZeneca (NYSE: [[ticker:AZN]]) and Pfizer (NYSE: [[ticker:PFE]]). 3Scan uses automation, machine learning, and artificial intelligence to digitize whole tissue samples. The company says its technology supports medical research and drug development.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan